Rhythm Pharmaceuticals, Inc., a leader in the biopharmaceutical industry, is pioneering innovative therapeutics for rare genetic diseases of obesity. Focused on the development and commercialization of its products, the company's premier offering is IMCIVREE, a groundbreaking melanocortin-4 receptor for the treatment of a host of rare obesities - including pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. Furthermore, Rhythm Pharmaceuticals is actively creating setmelanotide, which currently undergoes Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. Founded in 2008, Rhythm Pharmaceuticals was formerly known as Rhythm Metabolic, Inc. before undergoing a name change in October 2015. The company is headquartered in Boston, Massachusetts - a testament to its dedication to developing advanced medical treatments of the highest caliber.